Chemotherapy-Induced Neuropathy in Cancer Survivors
- PMID: 28063866
- PMCID: PMC5496793
- DOI: 10.1016/j.jpainsymman.2016.12.342
Chemotherapy-Induced Neuropathy in Cancer Survivors
Abstract
Context: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available.
Objectives: To evaluate between-group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n = 426) and did not (n = 197) develop CIN.
Methods: Survivors completed self-report questionnaires and underwent objective testing (i.e., light touch, pain sensation, cold sensation, vibration, muscle strength, grip strength, Purdue Pegboard test, Timed Get Up and Go test, Fullerton Advanced Balance test). Parametric and nonparametric statistics were used to compare between-group differences in study outcomes.
Results: Of the 426 survivors with CIN, 4.9% had CIN only in their upper extremities, 27.0% only in their lower extremities, and 68.1% in both their upper and lower extremities. Demographic and clinical characteristics associated with CIN included the following: older age, lower annual income, higher body mass index, a higher level of comorbidity, being born prematurely, receipt of a higher cumulative dose of chemotherapy, and a poorer functional status. Survivors with CIN had worse outcomes for all of the following objective measures: light touch, pain, temperature, vibration, upper and lower extremity function, and balance.
Conclusions: This study is the first to provide a detailed phenotypic characterization of CIN in cancer survivors who received a platinum and/or a taxane compound. These data can serve as a benchmark for future studies of CIN in cancer survivors.
Keywords: Chemotherapy-induced neuropathy; balance; cancer; chemotherapy; gait; pain; pain qualities; sensations; vibration.
Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
Figures



Similar articles
-
Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.Eur J Oncol Nurs. 2018 Feb;32:1-11. doi: 10.1016/j.ejon.2017.10.006. Epub 2017 Nov 7. Eur J Oncol Nurs. 2018. PMID: 29353626 Free PMC article.
-
Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.Support Care Cancer. 2019 Oct;27(10):3905-3912. doi: 10.1007/s00520-019-04695-3. Epub 2019 Feb 15. Support Care Cancer. 2019. PMID: 30770977 Free PMC article.
-
Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.J Pain Symptom Manage. 2018 Jul;56(1):88-97. doi: 10.1016/j.jpainsymman.2018.02.021. Epub 2018 Mar 7. J Pain Symptom Manage. 2018. PMID: 29524582 Free PMC article.
-
[Peripheral neuropathy as a side effect of chemotherapy and targeted therapy].Dtsch Med Wochenschr. 2018 Jul;113(13):970-978. doi: 10.1055/s-0043-120839. Epub 2018 Jul 4. Dtsch Med Wochenschr. 2018. PMID: 29972842 Review. German.
-
[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].Bull Cancer. 2018 Nov;105(11):1020-1032. doi: 10.1016/j.bulcan.2018.07.009. Epub 2018 Sep 20. Bull Cancer. 2018. PMID: 30244980 Review. French.
Cited by
-
Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology in breast cancer survivors with chronic paclitaxel-induced peripheral neuropathy.Mol Pain. 2019 Jan-Dec;15:1744806919878088. doi: 10.1177/1744806919878088. Mol Pain. 2019. PMID: 31486345 Free PMC article.
-
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients.Breast Cancer Res Treat. 2017 Jul;164(1):69-77. doi: 10.1007/s10549-017-4230-8. Epub 2017 Apr 3. Breast Cancer Res Treat. 2017. PMID: 28374323 Free PMC article.
-
Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect.Front Mol Biosci. 2021 May 7;8:643824. doi: 10.3389/fmolb.2021.643824. eCollection 2021. Front Mol Biosci. 2021. PMID: 34026827 Free PMC article. Review.
-
Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors.Mol Pain. 2018 Jan-Dec;14:1744806918816462. doi: 10.1177/1744806918816462. Epub 2018 Nov 14. Mol Pain. 2018. PMID: 30426838 Free PMC article.
-
Perceived stress is associated with a higher symptom burden in cancer survivors.Cancer. 2019 Dec 15;125(24):4509-4515. doi: 10.1002/cncr.32477. Epub 2019 Sep 10. Cancer. 2019. PMID: 31503333 Free PMC article.
References
-
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271. - PubMed
-
- Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967. - PubMed
-
- Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30:3687–3696. - PubMed
-
- Bennion AE, Molassiotis A. Qualitative research into the symptom experiences of adult cancer patients after treatments: a systematic review and meta-synthesis. Support Care Cancer. 2013;21:9–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical